DNA graphic

Funding Opportunities

Our comprehensive grant program attracts new scientific talent to the field and provides opportunities for researchers to pursue the most novel ideas as well as to advance proven approaches that improve treatment. Advancing fundamental through translational and clinical research.

In addition to funding lupus research, the Lupus Research Alliance recognizes, through the  Lupus Insight Prize, critical discoveries in an area of research that is applicable to the pathogenesis or treatment of lupus. These key findings, or insights have a high likelihood of generating further significant advances by applying the insight to lupus.

 

The Dr. William E. Paul Distinguished Innovator Grant in Lupus addresses the current lack of treatments in development that could arrest or reverse the disease. Providing funding for up to $1 million, this grant challenges exceptional scientists, from all relevant scientific disciplines, to uncover the root causes of lupus and present a compelling vision of how these discoveries would begin the drive to a cure, as well as prevention strategies.

Currently, we do not have any open grant mechanisms. However, we encourage you to contact us if you are interested in receiving future requests for proposals.

Please contact Diomaris Gonzalez at dgonzalez@lupusresearch.org if you would like additional information or have any questions about this grant.

The Lupus Insight Prize is awarded to an outstanding investigator who has developed a novel research insight in a scientific domain relevant to lupus. The $100,000 prize is not a lifetime achievement award. Instead, the Prize recognizes a specific insight and/or discovery and provides research funds to the institution of the awardee with the expectation that those funds will direct the talents of the Prize recipient toward further high impact research achievement and, specifically, toward application of the insight to lupus.

It is important to emphasize that the insight need not have been made specifically about lupus, but the insight should be applicable and applied, using the Prize funds, to understanding lupus pathogenesis or treatment.

Please visit www.lupusinsightprize.org for additional information.

Please contact Diomaris Gonzalez at dgonzalez@lupusresearch.org if you would like additional information or have any questions about this grant.

The Novel Research Grant program provides early-stage support with $300,000 grants over three years, used for high-risk, high-reward, idea-driven investigations into the fundamental mechanisms of lupus and its complications, and the explorations of novel targets, pathways, and technologies. The aim is to stimulate the study of underexplored avenues that can lead to the development of safer and more effective treatments.

Under our Target Identification in Lupus (TIL) grant program, investigators receive a three-year, up-to $600,000 award, to remove the barriers to new treatments and a possible cure. All research funded under the TIL program is based on realizable goals and designed for “translational” research – discoveries that become useful therapies in the near future, moving quickly from the laboratory to the patient’s bedside.

Currently, we do not have any open grant mechanisms. However, we encourage you to contact us if you are interested in receiving future requests for proposals.

Please contact Diomaris Gonzalez at dgonzalez@lupusresearch.org if you would like additional information or have any questions about this grant.

IICT Grants seek to stimulate exploration of novel therapeutic approaches. This programmatic approach is intended to augment Lupus Research Alliance’s current research portfolio in an effort to align supported research projects with the Lupus Research Alliance’s affiliate, Lupus Therapeutics and the Lupus Clinical Investigators Network (LuCIN) strategic objectives. The purpose of the Grant is to provide support one or more for well-justified investigator-initiated clinical trials (not fully funded by industry or other sources) designed to determine whether, and to what extent, promising new therapies can improve the lives of lupus patients. A primary focus is the evaluation of drugs that are currently approved for other indications and are available for use, known as drug re-purposing, which has been a major focus of the Lupus Research Alliance’s interest in drug development in lupus. The intention of this program is to eliminate the barriers that typically hinder lupus clinical trials, ensuring that scientifically-sound treatment approaches are tested in lupus patients as quickly as possible.

Applicants may request funding as follows: up to $3,000,000 in total over two or three years (inclusive of IDC at 10%) for non-drug study costs.

SUBMISSION PROCESS

Applicants will be required to submit their applications through proposalCENTRAL by September 4, 2018 by 8p.m. EDT. All applications must be submitted electronically through this online system at https://proposalcentral.altum.com First-time users must register and create a username and password. A User Guide and detailed submission instructions are available after signing into the application system to help Applicants navigate through the application process.

Download the complete RFA Here.

All scientific inquiries regarding application submission should be directed to Albert Roy at aroy@lupusresearch.org or 646-884-6071.

All administrative inquiries regarding application submission should be directed to:

Anisha Viswanathan
Program Manager
Lupus Therapeutics
aviswanathan@lupusresearch.org
646-884-6020

Diomaris Gonzalez
Director, Grant Programs
Lupus Research Alliance
dgonzalez@lupusresearch.org
646-884-6056

Click here for current grants